DefiniGEN

DefiniGEN creates human cell models to support drug discovery and preclinical research.

Cambridge, UK—Founded 2018

£4.8MTotal raised

DefiniGEN provides human cell products and services, creating predictive disease cell models for preclinical research and drug development.

Founders

Marcus Yeo

CEO

Marcus brings experience in health, pharma, and synthetic biology through founding and leadership roles at companies including DefiniGEN, AcuLive Therapeutics, and AscendBio.

Investors

Other26 November 2020
£3.3M
BGFLead
24Haymarket
29 June 2016
£1.5M
Cambridge EnterpriseLead
24 HaymarketLead
JM
Jonathan Milner
PI
Providence Investment Company
Parkwalk
CC
Cambridge Capital Group

Funding history

Other26 November 2020

£3.3M

DefiniGEN secures £3.3m in funding led by BGF to scale operations

BGF led the round with participation from 24Haymarket to support US expansion and site growth.

29 June 2016

£1.5M

DefiniGEN raises £1.5m in follow-on funding led by Cambridge Enterprise and 24 Haymarket

The follow-on investment will fund the commercial launch of new pancreatic and lung stem cell products.